Anne W Beaven

Summary

Affiliation: Duke University Medical Center
Country: USA

Publications

  1. pmc Radiotherapy dose-response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy
    Jennifer A Dorth
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Radiat Oncol 7:100. 2012
  2. doi request reprint A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
    Anne W Beaven
    Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 53:254-8. 2012
  3. doi request reprint Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma
    Anne W Beaven
    Division of Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Invest 29:214-9. 2011
  4. ncbi request reprint Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks
    Chris R Kelsey
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA
    Oncology (Williston Park) 26:1182-9, 1193. 2012
  5. ncbi request reprint Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?
    Chris R Kelsey
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncology (Williston Park) 24:1204-12. 2010
  6. ncbi request reprint Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant
    Anne W Beaven
    Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27710, USA
    Drugs Today (Barc) 43:461-73. 2007
  7. doi request reprint Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging
    Jennifer A Dorth
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 84:762-7. 2012
  8. ncbi request reprint The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature
    Anne W Beaven
    Division of Oncology, Duke University Medical Center, Durham, NC
    Support Cancer Ther 4:188-97. 2007

Detail Information

Publications8

  1. pmc Radiotherapy dose-response analysis for diffuse large B-cell lymphoma with a complete response to chemotherapy
    Jennifer A Dorth
    Department of Radiation Oncology, University Hospitals Seidman Cancer Center and Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106, USA
    Radiat Oncol 7:100. 2012
    ..To examine the efficacy of different radiation doses after achievement of a complete response to chemotherapy in diffuse large B-cell lymphoma (DLBCL)...
  2. doi request reprint A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma
    Anne W Beaven
    Duke University Medical Center, Durham, NC 27710, USA
    Leuk Lymphoma 53:254-8. 2012
    ..3%) for an overall response rate (ORR) of 50%. The combination of standard dose ibritumomab tiuxetan and bortezomib at 1.5 mg/m(2) is well tolerated with a promising response rate...
  3. doi request reprint Infusional mitoxantrone plus bolus melphalan as a stem cell transplant conditioning regimen for multiple myeloma
    Anne W Beaven
    Division of Oncology, Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA
    Cancer Invest 29:214-9. 2011
    ..Myelosuppression and mucositis were the most frequent adverse events. This regimen is well tolerated and the survival compares well to other transplant trials...
  4. ncbi request reprint Combined-modality therapy for early-stage Hodgkin lymphoma: maintaining high cure rates while minimizing risks
    Chris R Kelsey
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina, USA
    Oncology (Williston Park) 26:1182-9, 1193. 2012
    ..In favorable patients, as few as 2 cycles of ABVD have been shown to be effective. The current combined-modality approach seeks to maintain high cure rates but minimize risks by optimizing both chemotherapy and radiation therapy..
  5. ncbi request reprint Radiation therapy in the management of diffuse large B-cell lymphoma: still relevant?
    Chris R Kelsey
    Department of Radiation Oncology, Duke University Medical Center, Durham, North Carolina 27710, USA
    Oncology (Williston Park) 24:1204-12. 2010
    ..Finally, for patients with advanced DLBCL who are no longer responsive to systemic therapy, RT may provide rapid and durable palliation of local lymphoma-related symptoms...
  6. ncbi request reprint Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant
    Anne W Beaven
    Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27710, USA
    Drugs Today (Barc) 43:461-73. 2007
    ....
  7. doi request reprint Impact of consolidation radiation therapy in stage III-IV diffuse large B-cell lymphoma with negative post-chemotherapy radiologic imaging
    Jennifer A Dorth
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 84:762-7. 2012
    ..While consolidation radiation therapy (i.e., RT administered after chemotherapy) is routine treatment for patients with early-stage diffuse large B-cell lymphoma (DLBCL), the role of consolidation RT in stage III-IV DLBCL is controversial...
  8. ncbi request reprint The effect of palifermin on chemotherapyand radiation therapy-induced mucositis: a review of the current literature
    Anne W Beaven
    Division of Oncology, Duke University Medical Center, Durham, NC
    Support Cancer Ther 4:188-97. 2007
    ....